Description: Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.
Home Page: kaleido.com
KLDO Technical Analysis
65 Hayden Avenue
Lexington,
MA
02421
United States
Phone:
617 674 9000
Officers
| Name | Title |
|---|---|
| Ms. Kimberly Hocknell | Sr. VP of Technical Operations |
| Ms. Susan Stewart J.D., L.L.M. | Chief Regulatory Affairs ? Advisor |
| Dr. Mark A. Wingertzahn Ph.D. | Sr. VP of R&D and Head of Devel. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.0044 |
| Price-to-Sales TTM: | 0.0425 |
| IPO Date: | 2019-02-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 76 |